Toxicity Management and Symptom Control in Advanced RCC: Playbook Update

STATEMENT OF NEED

Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations granted approval. While these treatments demonstrate superior efficacy compared with previous standards, patients may experience adverse events that carry the risk of dose reductions or drug discontinuations, and safety and tolerability remain crucial considerations in the care of patients receiving novel therapies for RCC (Tucci et al, 2024). Therefore, it is vital that nurses remain up to date on prevention and management strategies for toxicities associated with novel immunotherapies and targeted therapies in order to deliver optimal care to their patients. In this activity, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, Director of the GU Clinical Trials Program at David Geffen School of Medicine at UCLA and the Institute of Urologic Oncology at UCLA, provides a playbook update on toxicity management and symptom control in advanced RCC.

TARGET AUDIENCE

Oncology and urology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals involved in the treatment of patients with renal cell carcinoma (RCC).